Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tobacco Health Document Submission, 49527-49528 [2013-19683]
Download as PDF
Federal Register / Vol. 78, No. 157 / Wednesday, August 14, 2013 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0377]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Tobacco Health
Document Submission
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by September
13, 2013.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0654. Also
include the FDA docket number found
in brackets in the heading of this
document.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5156, daniel.gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
tkelley on DSK3SPTVN1PROD with NOTICES
Tobacco Health Document
Submission—(OMB Control Number
0910–0654)—Extension
On June 22, 2009, the President
signed the Family Smoking Prevention
and Tobacco Control Act (Tobacco
Control Act) (Pub. L. 111–31) into law.
The Tobacco Control Act amended the
Federal Food, Drug, and Cosmetic Act
(the FD&C Act) by adding, among other
things, a new chapter granting FDA
important authority to regulate the
manufacture, marketing, and
distribution of tobacco products to
protect the public health generally and
to reduce tobacco use by minors. The
Tobacco Control Act created many new
VerDate Mar<15>2010
16:16 Aug 13, 2013
Jkt 229001
requirements for the tobacco industry.
Section 101 of the Tobacco Control Act
amended the FD&C Act by adding,
among other things, section 904(a)(4)
(21 U.S.C. 387d(a)(4)).
Section 904(a)(4) of the FD&C Act
requires each tobacco product
manufacturer or importer, or agent
thereof, to submit all documents
developed after June 22, 2009, ‘‘that
relate to health, toxicological,
behavioral, or physiologic effects of
current or future tobacco products, their
constituents (including smoke
constituents), ingredients, components,
and additives’’ (herein referred to as
‘‘tobacco health documents’’).
FDA announced the availability of a
guidance on this collection in the
Federal Register of April 20, 2010 (75
FR 20606), and requested tobacco health
documents that were created during the
period from June 23, 2009, through
December 31, 2009. The guidance stated
that information required under section
904(a)(4) of the FD&C Act must be
submitted to FDA beginning December
22, 2009. Further, FDA stated it would
publish a revised guidance specifying
the timing of subsequent reporting. FDA
is in the process of revising the April
2010 guidance but will continue
collecting documents created during the
specified period from any
manufacturers, importers, or their
agents who still have documents to
submit.
FDA has been collecting the
information submitted under section
904(a)(4) of the FD&C Act through a
facilitative electronic form and through
a paper form (Form FDA 3743) for those
individuals who choose not to use the
electronic method. In both forms, FDA
is requesting the following information
from firms that have not already
reported or still have documents to
report:
• Submitter identification: Submitter
type, company name, address, country,
company headquarters Dun and
Bradstreet number, and company
headquarters Facility Establishment
Identifier number;
• Submitter point of contact: Contact
name, title, position title, email,
telephone, and fax; and
• Submission format and contents (as
applicable):
Æ Electronic documents: Media type,
media quantity, size of submission,
quantity of documents, file type, and
file software;
Æ Paper documents: Quantity of
documents, quantity of volumes, and
quantity of boxes; and
Æ Whether or not a submission is
being provided.
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
49527
• Confirmation statement (with
identification and signature of submitter
including name, company name,
address, position title, email, telephone,
and fax); and
• Document categorization (as
applicable): Relationship of the
document or set of documents to the
following:
Æ Health, behavioral, toxicological, or
physiological effects;
Æ Specific current or future tobacco
product(s);
Æ Class of current or future tobacco
product(s);
Æ Specific ingredient(s),
constituent(s), component(s), or
additive(s);
Æ Class of ingredient(s),
constituent(s), component(s), or
additive(s).
• Document readability and
accessibility: Keywords; glossary or
explanation of any abbreviations, jargon,
or internal (e.g., code) names; special
instructions for loading or compiling
submission; and
• Document metadata: Date document
was created, document author(s),
document recipient(s), document
custodian, document title or
identification number, beginning and
ending Bates numbers, and Bates
number ranges for documents attached
to a submitted email.
In addition to the electronic and
paper forms, the guidance that FDA
issued in April 2010 (75 FR 20606) was
intended to assist persons making
tobacco health document submissions.
For further assistance, FDA is providing
a technical guide, embedded hints, and
a Web tutorial on the electronic portal.
The estimated 50 hours per response
burden is based on the average burden
estimate among all four respondents.
Therefore, on an individual basis, the
actual burden per respondent may be
higher or lower than the 50 hours
estimate because it is an average value.
FDA currently is evaluating the
classification/coding recommendations
and will revisit this issue in future
guidance. The number of documents
received each year since the original
collection period has fallen to less than
5 percent of the number received in the
original collection period. FDA expects
this is because documents created
within the specified period have already
been submitted. Also, the number of
respondents who still have documents
to submit has decreased. Therefore, FDA
estimates the biannual burden of the
continuation of this collection to be at
most, 5 percent of the original burden.
In the Federal Register of April 10,
2013 (78 FR 21379), FDA published a
60-day notice requesting public
E:\FR\FM\14AUN1.SGM
14AUN1
49528
Federal Register / Vol. 78, No. 157 / Wednesday, August 14, 2013 / Notices
comment on the proposed collection of
information. FDA received five
comments; some comments raised more
than one issue. Comments relevant to
the information request are addressed in
this document.
(Comment 1) One comment indicated
that the intent of the notice was unclear
and suggested that FDA revise and
republish the notice to provide clarity
and allow stakeholders more
opportunity to comment.
(Response) FDA published the 60-day
information collection notice (78 FR
21379) to provide an opportunity for
comment on its proposed extension of
an existing collection of information.
The collection includes health tobacco
documents created during the period
June 23, 2009, through December 31,
2009, that have not been submitted to
FDA. FDA does not believe that revision
of the April 2013 notice would add
clarity or provide a more meaningful
opportunity to comment. FDA has met
the requirements for the proposed
extension of this collection of
information.
(Comment 2) Another comment stated
that FDA is outside its statutory
authority in recommending coding/
classification and places an unnecessary
and unreasonable burden on the
industry with no benefit to FDA in
collecting this information.
(Response) Section 904(a)(4) of the
FD&C Act grants FDA the authority to
collect health document information as
specified in this document. The
classification and coding mentioned in
this document are recommendations
from the April 2010 guidance, and FDA
will reevaluate and revisit this issue in
developing future guidance.
(Comment 3) Two comments
indicated that the timing and burden for
this collection are underestimated.
(Response) The estimated burden of
50 hours per response is based on the
average burden estimate among four
respondents. Therefore, on an
individual basis, the actual burden per
respondent may be higher or lower than
the 50 hours estimate because it is an
average value. FDA notes that the
number of documents received since the
original collection period has decreased
each year and is currently less than 5
percent of the number received in the
year following the Agency’s original
announcement. FDA expects that this
collection of information will decrease
by 7,600 hours because most documents
created within the specified period have
been submitted, and the number of
respondents who still have documents
to submit has decreased. Therefore, FDA
estimates the biannual burden of the
continuation of this collection to be, at
most, 5 percent of the original burden.
(Comment 4) One comment indicated
that the information requested in this
collection is from too narrow a
collection window, and another
comment stated that the collection of
2009 information in 2013 is not
necessary.
(Response) Section 904(a)(4) of the
FD&C Act sets out an ongoing
requirement for the submission of
tobacco health documents. FDA is in the
process of revising the April 2010
guidance to specify the timing of
subsequent submissions. However, the
Agency will continue collecting
documents created during the period
from June 23, 2009, through December
31, 2009, from any manufacturers,
importers, or their agents who still have
documents to submit.
(Comment 5) Several comments
referred to the 2009 draft guidance (74
FR 68629, December 28, 2009) and to
previously submitted comments on the
2009 draft guidance.
(Response) The 2009 draft guidance
was superseded by publication of the
April 2010 guidance. FDA considered
comments on the 2009 draft guidance
while developing the April 2010
guidance. Comments on Agency
guidance are welcome at any time (21
CFR 10.115(g)(5)), and comments
submitted on the April 2010 guidance
will be considered when the guidance is
revised.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Activity
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
Tobacco Health Document Submissions and Form FDA
3743 ..................................................................................
4
2
8
50
400
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: August 8, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–19683 Filed 8–13–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
tkelley on DSK3SPTVN1PROD with NOTICES
[Docket No. FDA–2013–N–0842]
Consolidation of Wound Care Products
Containing Live Cells
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
VerDate Mar<15>2010
16:16 Aug 13, 2013
Jkt 229001
The Food and Drug
Administration (FDA) is transferring
oversight responsibilities for certain
wound care products containing live
cells from the Center for Devices and
Radiological Health (CDRH) to the
Center for Biologics Evaluation and
Research (CBER). This consolidation
initiative provides the opportunity to
further develop and coordinate
scientific and regulatory activities
between CDRH and CBER. FDA believes
that as more wound care products
containing live cells are developed such
consolidation is necessary for both
efficient and consistent Agency action.
SUMMARY:
John
Barlow Weiner, Office of Combination
Products, Food and Drug
Administration, 10903 New Hampshire
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
Ave., Bldg. 32, rm. 5130, Silver Spring,
MD 20993, 301–796–8930,
john.weiner@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Consolidation of Approved Wound
Care Products Containing Live Cells in
CBER
On August 14, 2013, primary
responsibility for regulating the
following approved products: P950032,
P960007, P000036, P010016, (all with
product code MGR); H990013 (product
code PBD); and H990002 (product code
OCE), and all supplements included
therein, was transferred from the Office
of Device Evaluation, CDRH, to the
Office of Cellular, Tissue and Gene
Therapies, CBER. The jurisdictional
assignment of these products to CBER is
E:\FR\FM\14AUN1.SGM
14AUN1
Agencies
[Federal Register Volume 78, Number 157 (Wednesday, August 14, 2013)]
[Notices]
[Pages 49527-49528]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-19683]
[[Page 49527]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0377]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Tobacco Health
Document Submission
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
September 13, 2013.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0654.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-5156,
daniel.gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Tobacco Health Document Submission--(OMB Control Number 0910-0654)--
Extension
On June 22, 2009, the President signed the Family Smoking
Prevention and Tobacco Control Act (Tobacco Control Act) (Pub. L. 111-
31) into law. The Tobacco Control Act amended the Federal Food, Drug,
and Cosmetic Act (the FD&C Act) by adding, among other things, a new
chapter granting FDA important authority to regulate the manufacture,
marketing, and distribution of tobacco products to protect the public
health generally and to reduce tobacco use by minors. The Tobacco
Control Act created many new requirements for the tobacco industry.
Section 101 of the Tobacco Control Act amended the FD&C Act by adding,
among other things, section 904(a)(4) (21 U.S.C. 387d(a)(4)).
Section 904(a)(4) of the FD&C Act requires each tobacco product
manufacturer or importer, or agent thereof, to submit all documents
developed after June 22, 2009, ``that relate to health, toxicological,
behavioral, or physiologic effects of current or future tobacco
products, their constituents (including smoke constituents),
ingredients, components, and additives'' (herein referred to as
``tobacco health documents'').
FDA announced the availability of a guidance on this collection in
the Federal Register of April 20, 2010 (75 FR 20606), and requested
tobacco health documents that were created during the period from June
23, 2009, through December 31, 2009. The guidance stated that
information required under section 904(a)(4) of the FD&C Act must be
submitted to FDA beginning December 22, 2009. Further, FDA stated it
would publish a revised guidance specifying the timing of subsequent
reporting. FDA is in the process of revising the April 2010 guidance
but will continue collecting documents created during the specified
period from any manufacturers, importers, or their agents who still
have documents to submit.
FDA has been collecting the information submitted under section
904(a)(4) of the FD&C Act through a facilitative electronic form and
through a paper form (Form FDA 3743) for those individuals who choose
not to use the electronic method. In both forms, FDA is requesting the
following information from firms that have not already reported or
still have documents to report:
Submitter identification: Submitter type, company name,
address, country, company headquarters Dun and Bradstreet number, and
company headquarters Facility Establishment Identifier number;
Submitter point of contact: Contact name, title, position
title, email, telephone, and fax; and
Submission format and contents (as applicable):
[cir] Electronic documents: Media type, media quantity, size of
submission, quantity of documents, file type, and file software;
[cir] Paper documents: Quantity of documents, quantity of volumes,
and quantity of boxes; and
[cir] Whether or not a submission is being provided.
Confirmation statement (with identification and signature
of submitter including name, company name, address, position title,
email, telephone, and fax); and
Document categorization (as applicable): Relationship of
the document or set of documents to the following:
[cir] Health, behavioral, toxicological, or physiological effects;
[cir] Specific current or future tobacco product(s);
[cir] Class of current or future tobacco product(s);
[cir] Specific ingredient(s), constituent(s), component(s), or
additive(s);
[cir] Class of ingredient(s), constituent(s), component(s), or
additive(s).
Document readability and accessibility: Keywords; glossary
or explanation of any abbreviations, jargon, or internal (e.g., code)
names; special instructions for loading or compiling submission; and
Document metadata: Date document was created, document
author(s), document recipient(s), document custodian, document title or
identification number, beginning and ending Bates numbers, and Bates
number ranges for documents attached to a submitted email.
In addition to the electronic and paper forms, the guidance that
FDA issued in April 2010 (75 FR 20606) was intended to assist persons
making tobacco health document submissions. For further assistance, FDA
is providing a technical guide, embedded hints, and a Web tutorial on
the electronic portal.
The estimated 50 hours per response burden is based on the average
burden estimate among all four respondents. Therefore, on an individual
basis, the actual burden per respondent may be higher or lower than the
50 hours estimate because it is an average value. FDA currently is
evaluating the classification/coding recommendations and will revisit
this issue in future guidance. The number of documents received each
year since the original collection period has fallen to less than 5
percent of the number received in the original collection period. FDA
expects this is because documents created within the specified period
have already been submitted. Also, the number of respondents who still
have documents to submit has decreased. Therefore, FDA estimates the
biannual burden of the continuation of this collection to be at most, 5
percent of the original burden.
In the Federal Register of April 10, 2013 (78 FR 21379), FDA
published a 60-day notice requesting public
[[Page 49528]]
comment on the proposed collection of information. FDA received five
comments; some comments raised more than one issue. Comments relevant
to the information request are addressed in this document.
(Comment 1) One comment indicated that the intent of the notice was
unclear and suggested that FDA revise and republish the notice to
provide clarity and allow stakeholders more opportunity to comment.
(Response) FDA published the 60-day information collection notice
(78 FR 21379) to provide an opportunity for comment on its proposed
extension of an existing collection of information. The collection
includes health tobacco documents created during the period June 23,
2009, through December 31, 2009, that have not been submitted to FDA.
FDA does not believe that revision of the April 2013 notice would add
clarity or provide a more meaningful opportunity to comment. FDA has
met the requirements for the proposed extension of this collection of
information.
(Comment 2) Another comment stated that FDA is outside its
statutory authority in recommending coding/classification and places an
unnecessary and unreasonable burden on the industry with no benefit to
FDA in collecting this information.
(Response) Section 904(a)(4) of the FD&C Act grants FDA the
authority to collect health document information as specified in this
document. The classification and coding mentioned in this document are
recommendations from the April 2010 guidance, and FDA will reevaluate
and revisit this issue in developing future guidance.
(Comment 3) Two comments indicated that the timing and burden for
this collection are underestimated.
(Response) The estimated burden of 50 hours per response is based
on the average burden estimate among four respondents. Therefore, on an
individual basis, the actual burden per respondent may be higher or
lower than the 50 hours estimate because it is an average value. FDA
notes that the number of documents received since the original
collection period has decreased each year and is currently less than 5
percent of the number received in the year following the Agency's
original announcement. FDA expects that this collection of information
will decrease by 7,600 hours because most documents created within the
specified period have been submitted, and the number of respondents who
still have documents to submit has decreased. Therefore, FDA estimates
the biannual burden of the continuation of this collection to be, at
most, 5 percent of the original burden.
(Comment 4) One comment indicated that the information requested in
this collection is from too narrow a collection window, and another
comment stated that the collection of 2009 information in 2013 is not
necessary.
(Response) Section 904(a)(4) of the FD&C Act sets out an ongoing
requirement for the submission of tobacco health documents. FDA is in
the process of revising the April 2010 guidance to specify the timing
of subsequent submissions. However, the Agency will continue collecting
documents created during the period from June 23, 2009, through
December 31, 2009, from any manufacturers, importers, or their agents
who still have documents to submit.
(Comment 5) Several comments referred to the 2009 draft guidance
(74 FR 68629, December 28, 2009) and to previously submitted comments
on the 2009 draft guidance.
(Response) The 2009 draft guidance was superseded by publication of
the April 2010 guidance. FDA considered comments on the 2009 draft
guidance while developing the April 2010 guidance. Comments on Agency
guidance are welcome at any time (21 CFR 10.115(g)(5)), and comments
submitted on the April 2010 guidance will be considered when the
guidance is revised.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Tobacco Health Document Submissions and Form FDA 3743.............. 4 2 8 50 400
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: August 8, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-19683 Filed 8-13-13; 8:45 am]
BILLING CODE 4160-01-P